Tags

Type your tag names separated by a space and hit enter

Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive-Compulsive and Impulsive Features in Adults with Binge Eating Disorder.
Eur Eat Disord Rev. 2016 May; 24(3):223-31.EE

Abstract

In a published 11-week, placebo-controlled trial, 50 and 70 mg/d lisdexamfetamine dimesylate (LDX), but not 30 mg/d LDX, significantly reduced binge eating days (primary endpoint) in adults with binge eating disorder (BED). This report provides descriptions of LDX effects on secondary endpoints (Binge Eating Scale [BES]; Three-Factor Eating Questionnaire [TFEQ]; Yale-Brown Obsessive Compulsive Scale modified for Binge Eating [Y-BOCS-BE]; and the Barratt Impulsiveness Scale, version 11 [BIS-11]) from that study. Week 11 least squares mean treatment differences favoured all LDX doses over placebo on the BES (p ≤ 0.03), TFEQ Disinhibition and Hunger subscales (all p < 0.05), and Y-BOCS-BE total, obsessive, and compulsive scales (all p ≤ 0.02) and on BIS-11 total score at 70 mg/d LDX (p = 0.015) and the TFEQ Cognitive Restraint subscale at 30 and 70 mg/d LDX (both p < 0.05). These findings indicate that LDX decreased global binge eating severity and obsessive-compulsive and impulsive features of BED in addition to binge eating days.

Authors+Show Affiliations

University of Cincinnati College of Medicine, Cincinnati, OH, USA. Lindner Center of HOPE, Mason, OH, USA.Neuropsychiatric Research Institute, Fargo, ND, USA.Washington University School of Medicine, St. Louis, MO, USA.Shire, Wayne, PA, USA.Shire, Wayne, PA, USA.Shire, Wayne, PA, USA.CSL Behring, King of Prussia, PA, USA (previously employed at Shire).Shire, Wayne, PA, USA.McLean Hospital/Harvard Medical School, Belmont, MA, USA.

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26621156

Citation

McElroy, Susan L., et al. "Lisdexamfetamine Dimesylate Effects On Binge Eating Behaviour and Obsessive-Compulsive and Impulsive Features in Adults With Binge Eating Disorder." European Eating Disorders Review : the Journal of the Eating Disorders Association, vol. 24, no. 3, 2016, pp. 223-31.
McElroy SL, Mitchell JE, Wilfley D, et al. Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive-Compulsive and Impulsive Features in Adults with Binge Eating Disorder. Eur Eat Disord Rev. 2016;24(3):223-31.
McElroy, S. L., Mitchell, J. E., Wilfley, D., Gasior, M., Ferreira-Cornwell, M. C., McKay, M., Wang, J., Whitaker, T., & Hudson, J. I. (2016). Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive-Compulsive and Impulsive Features in Adults with Binge Eating Disorder. European Eating Disorders Review : the Journal of the Eating Disorders Association, 24(3), 223-31. https://doi.org/10.1002/erv.2418
McElroy SL, et al. Lisdexamfetamine Dimesylate Effects On Binge Eating Behaviour and Obsessive-Compulsive and Impulsive Features in Adults With Binge Eating Disorder. Eur Eat Disord Rev. 2016;24(3):223-31. PubMed PMID: 26621156.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive-Compulsive and Impulsive Features in Adults with Binge Eating Disorder. AU - McElroy,Susan L, AU - Mitchell,James E, AU - Wilfley,Denise, AU - Gasior,Maria, AU - Ferreira-Cornwell,M Celeste, AU - McKay,Michael, AU - Wang,Jiannong, AU - Whitaker,Timothy, AU - Hudson,James I, Y1 - 2015/12/01/ PY - 2015/04/28/received PY - 2015/09/17/revised PY - 2015/10/26/accepted PY - 2015/12/2/entrez PY - 2015/12/2/pubmed PY - 2016/8/23/medline KW - binge eating disorder KW - impulsivity KW - lisdexamfetamine dimesylate KW - obsessive-compulsive SP - 223 EP - 31 JF - European eating disorders review : the journal of the Eating Disorders Association JO - Eur Eat Disord Rev VL - 24 IS - 3 N2 - In a published 11-week, placebo-controlled trial, 50 and 70 mg/d lisdexamfetamine dimesylate (LDX), but not 30 mg/d LDX, significantly reduced binge eating days (primary endpoint) in adults with binge eating disorder (BED). This report provides descriptions of LDX effects on secondary endpoints (Binge Eating Scale [BES]; Three-Factor Eating Questionnaire [TFEQ]; Yale-Brown Obsessive Compulsive Scale modified for Binge Eating [Y-BOCS-BE]; and the Barratt Impulsiveness Scale, version 11 [BIS-11]) from that study. Week 11 least squares mean treatment differences favoured all LDX doses over placebo on the BES (p ≤ 0.03), TFEQ Disinhibition and Hunger subscales (all p < 0.05), and Y-BOCS-BE total, obsessive, and compulsive scales (all p ≤ 0.02) and on BIS-11 total score at 70 mg/d LDX (p = 0.015) and the TFEQ Cognitive Restraint subscale at 30 and 70 mg/d LDX (both p < 0.05). These findings indicate that LDX decreased global binge eating severity and obsessive-compulsive and impulsive features of BED in addition to binge eating days. SN - 1099-0968 UR - https://www.unboundmedicine.com/medline/citation/26621156/Lisdexamfetamine_Dimesylate_Effects_on_Binge_Eating_Behaviour_and_Obsessive_Compulsive_and_Impulsive_Features_in_Adults_with_Binge_Eating_Disorder_ L2 - https://doi.org/10.1002/erv.2418 DB - PRIME DP - Unbound Medicine ER -